The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

Michael J. Landine net worth and biography

Michael Landine Biography and Net Worth

SVP of Alkermes

Mike Landine serves as Alkermes’ Senior Vice President of Corporate Development. In this role, Mr. Landine is responsible for overseeing the organization’s Corporate Affairs and Investor Relations functions.

Prior to leading Corporate Development, Mr. Landine served as Alkermes’ Chief Financial Officer and Treasurer from 1988 until 1998. He served on the Board of Directors of Kopin Corporation from 2003 to 2019 and the Board of Directors of GTC Biotherapeutics from 2005 to 2010.

Mr. Landine earned a bachelor’s degree in Accounting from Bentley University and previously was a Certified Public Accountant.

What is Michael J. Landine's net worth?: The estimated net worth of Michael J. Landine is at least $6.77 million as of May 3rd, 2022. Mr. Landine owns 232,306 shares of Alkermes stock worth more than $6,774,043 as of December 30th. This net worth estimate does not reflect any other investments that Mr. Landine may own. Learn More about Michael J. Landine's net worth.
How do I contact Michael J. Landine?: The corporate mailing address for Mr. Landine and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Michael J. Landine's contact information.
Has Michael J. Landine been buying or selling shares of Alkermes?: Michael J. Landine has not been actively trading shares of Alkermes in the last ninety days. Most recently, Michael J. Landine sold 25,000 shares of the business's stock in a transaction on Tuesday, May 3rd. The shares were sold at an average price of $28.62, for a transaction totalling $715,500.00. Following the completion of the sale, the senior vice president now directly owns 232,306 shares of the company's stock, valued at $6,648,597.72. Learn More on Michael J. Landine's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (Chairman & CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 7 times. They sold a total of 158,155 shares worth more than $4,865,621.63. The most recent insider tranaction occured on December, 9th when EVP Craig C Hopkinson sold 61,151 shares worth more than $1,961,112.57. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 12/9/2024.

Michael J. Landine Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2022	Sell	25,000	$28.62	$715,500.00	232,306
5/7/2021	Sell	19,477	$22.10	$430,441.70	236,258
5/12/2020	Sell	18,000	$15.75	$283,500.00	219,822
5/5/2020	Sell	25,000	$14.06	$351,500.00	226,822
3/24/2020	Sell	25,000	$13.91	$347,750.00	226,822
11/13/2019	Sell	20,000	$19.70	$394,000.00	205,122
11/6/2019	Sell	20,000	$19.76	$395,200.00	205,122
5/22/2019	Sell	20,000	$24.93	$498,600.00	193,426
3/14/2019	Sell	25,000	$33.05	$826,250.00	210,122
3/7/2019	Sell	20,000	$32.07	$641,400.00	205,122
5/24/2018	Sell	20,000	$45.22	$904,400.00	192,644
5/17/2018	Sell	20,000	$46.14	$922,800.00	192,644
11/1/2017	Sell	15,000	$48.71	$730,650.00	178,693
5/18/2017	Sell	10,000	$57.23	$572,300.00	167,370
5/11/2017	Sell	10,000	$57.01	$570,100.00	172,370
11/30/2016	Sell	10,000	$57.51	$575,100.00	165,659
4/20/2016	Sell	16,875	$41.09	$693,393.75	159,419
12/7/2015	Sell	3,750	$73.02	$273,825.00	141,324
12/1/2015	Sell	10,000	$72.18	$721,800.00	141,324
9/17/2015	Sell	10,000	$71.20	$712,000.00	138,680
9/10/2015	Sell	10,000	$67.61	$676,100.00	138,680
12/9/2014	Sell	18,000	$56.82	$1,022,760.00
9/18/2014	Sell	15,000	$45.60	$684,000.00
7/3/2014	Sell	7,000	$51.31	$359,170.00
6/26/2014	Sell	10,000	$49.92	$499,200.00
6/19/2014	Sell	10,000	$47.01	$470,100.00

Michael J. Landine Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $29.16

$28.87

$29.42

50 Day Range

MA: $28.93

$25.70

$31.46

2 Week Range

Now: $29.16

$22.90

$32.88

Volume

237,216 shs

Average Volume

1,800,449 shs

Market Capitalization

$4.72 billion

P/E Ratio

14.95

Dividend Yield

N/A

Beta

0.49

Vladimir Lenin was right…

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.